RxDoctor Payments Data

Anays Suarez, NP

Nurse Practitioner · Miami, FLNPI 1063964583

Payments from drug & device makers

$5,700in general payments, 2019–2025

Across 268 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$926
  • Lilly USA, LLC$418
  • E.r. Squibb & Sons, L.L.C.$387
  • Incyte Corporation$379
  • Sanofi$336
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,42895%
  • Education$2725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,700 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$17,349
Medicare patients
40
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa26$562,943
Dupixent PenDupilumab87$335,043
Cosentyx Sensoready (2 Pens)Secukinumab33$256,447
TremfyaGuselkumab17$238,308
Taltz AutoinjectorIxekizumab29$220,897
OpzeluraRuxolitinib Phosphate104$211,430
Cosentyx Unoready PenSecukinumab18$165,489
Taltz Autoinjector (2 Pack)Ixekizumab11$151,540
Dupixent SyringeDupilumab13$55,707
ZoryveRoflumilast50$43,147
JubliaEfinaconazole30$26,372
VtamaTapinarof16$22,734
Fluorouracil271$22,137
Azelaic Acid117$13,668
Clobetasol Propionate238$12,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$926$238,30817 claims
Incyte CorporationOpzelura$379$211,430104 claims
Arcutis Biotherapeutics, Inc.Zoryve$15$43,14750 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$60$26,37230 claims
Dermavant Sciences, Inc.Vtama$17$22,73416 claims
LEO Pharma Inc.Finacea$40$10,01424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →